Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

Hepatocyte growth factor (HGF)/c‐Met pathway dysregulation is a mechanism for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Ficlatuzumab (AV‐299; SCH 900105), a humanized IgG(1)κ HGF inhibitory monoclonal antibody, prevents HGF/c‐Met pathway ligand–mediated activation. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Eng‐Huat, Lim, Wan‐Teck, Ahn, Myung‐Ju, Ng, Quan‐Sing, Ahn, Jin Seok, Shao‐Weng Tan, Daniel, Sun, Jong‐Mu, Han, May, Payumo, Francis C., McKee, Krista, Yin, Wei, Credi, Marc, Agarwal, Shefali, Jac, Jaroslaw, Park, Keunchil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032914/
https://www.ncbi.nlm.nih.gov/pubmed/29346833
http://dx.doi.org/10.1002/cpdd.427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032914/
https://www.ncbi.nlm.nih.gov/pubmed/29346833
http://dx.doi.org/10.1002/cpdd.427

Ejemplares similares